Latest Content

A comparison of TrumpRx.gov prices against UK National Health Service pharmacy payouts found that drugs from several major manufacturers remain significantly cheaper under the British system.

Ankit Jain, CEO, Co-Founder, Infinitus touches on the approach to human oversight in an effort to build trust in autonomous patient access workflows by keeping humans and AI in a continuous feedback loop.

Ankit Jain, CEO, Co-Founder, Infinitus, discusses how AI-native patient access infrastructure appears to be less about replacing care teams and more about eliminating the friction between diagnosis and therapy initiation.

Matthew Turner, President of Patient Affordability, Paysign, discusses Paysign's approach to measuring copay program value in an effort to move beyond simple redemption counts toward a more complete picture of patient adherence.

In the final part of his conversation with Pharmaceutical Executive, Aravo CCO Dave Rusher discusses the various regulatory updates around the world in the pharma and AI space.

Limited patient populations require sponsors to adapt their practices when working in the rare disease space.

While digital clinical trials provide more opportunity, they also present unique challenges that can significantly impact the trial results.

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing manufacturers toward more sophisticated, partnership-driven program designs.

Matthew Turner, President of Patient Affordability, Paysign discusses how next-generation copay assistance appears to be less about consolidating services under one vendor and more about assembling best-in-class partnerships.

The funding rounds are part of a broader effort to advance next-generation T-cell engager platforms targeting cancers.

FDA has approved Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis, offering adults and adolescents a once-daily pill that blocks the IL-23 receptor.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, mentions how eClinical Solutions positioned its elluminate platform as part of an effort to help sponsors meet heightened evidence and oversight demands.

Faruk Capan provides insights into the future of proprietary AI platforms.